Aurinia Pharmaceuticals I... (AUPH)
Aurinia Pharmaceuticals Statistics
Share Statistics
Aurinia Pharmaceuticals has 136.65M shares outstanding. The number of shares has increased by -3.97% in one year.
| Shares Outstanding | 136.65M |
| Shares Change (YoY) | -3.97% |
| Shares Change (QoQ) | -4.08% |
| Owned by Institutions (%) | 40.33% |
| Shares Floating | 121.5M |
| Failed to Deliver (FTD) Shares | 755 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 11.49M, so 8.37% of the outstanding shares have been sold short.
| Short Interest | 11.49M |
| Short % of Shares Out | 8.37% |
| Short % of Float | 8.42% |
| Short Ratio (days to cover) | 10.46 |
Valuation Ratios
The PE ratio is 223.34 and the forward PE ratio is 10.79. Aurinia Pharmaceuticals's PEG ratio is -2.08.
| PE Ratio | 223.34 |
| Forward PE | 10.79 |
| PS Ratio | 5.46 |
| Forward PS | 2.7 |
| PB Ratio | 3.4 |
| P/FCF Ratio | 29.13 |
| PEG Ratio | -2.08 |
Enterprise Valuation
Aurinia Pharmaceuticals has an Enterprise Value (EV) of 1.28B.
| EV / Sales | 5.45 |
| EV / EBITDA | 40.36 |
| EV / EBIT | 28.85 |
| EV / FCF | 29.03 |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.21.
| Current Ratio | 4.57 |
| Quick Ratio | 4.17 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.5 |
| Debt / FCF | 1.8 |
| Interest Coverage | -0.97 |
Financial Efficiency
Return on Equity is 1.52% and Return on Invested Capital is -0.77%.
| Return on Equity | 1.52% |
| Return on Assets | 1.04% |
| Return on Invested Capital | -0.77% |
| Revenue Per Employee | $1.81M |
| Profits Per Employee | $44.25K |
| Employee Count | 130 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0.72 |
Taxes
| Income Tax | 1.7M |
| Effective Tax Rate | 22.77% |
Stock Price Statistics
The stock price has increased by 66.32% in the last 52 weeks. The beta is 1.22, so Aurinia Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | 66.32% |
| 50-Day Moving Average | 8.02 |
| 200-Day Moving Average | 7.55 |
| Relative Strength Index (RSI) | 54.62 |
| Average Volume (20 Days) | 1.4M |
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.
| Revenue | 235.13M |
| Gross Profit | 206.88M |
| Operating Income | -4.69M |
| Net Income | 5.75M |
| EBITDA | 31.73M |
| EBIT | 12.28M |
| Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has 83.43M in cash and 79.37M in debt, giving a net cash position of 4.06M.
| Cash & Cash Equivalents | 83.43M |
| Total Debt | 79.37M |
| Net Cash | 4.06M |
| Retained Earnings | -936.57M |
| Total Assets | 550.64M |
| Working Capital | 348.83M |
Cash Flow
In the last 12 months, operating cash flow was 44.39M and capital expenditures -281K, giving a free cash flow of 44.11M.
| Operating Cash Flow | 44.39M |
| Capital Expenditures | -281K |
| Free Cash Flow | 44.11M |
| FCF Per Share | 0.31 |
Margins
Gross margin is 87.99%, with operating and profit margins of -1.99% and 2.45%.
| Gross Margin | 87.99% |
| Operating Margin | -1.99% |
| Pretax Margin | 3.17% |
| Profit Margin | 2.45% |
| EBITDA Margin | 13.49% |
| EBIT Margin | -1.99% |
| FCF Margin | 18.76% |
Dividends & Yields
AUPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.45% |
| FCF Yield | 3.43% |
Analyst Forecast
The average price target for AUPH is $11.5, which is 42% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 42% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Nov 8, 2013. It was a backward split with a ratio of 1:50.
| Last Split Date | Nov 8, 2013 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 7 |